Oral contraceptives: therapeutics versus adverse reactions, with an outlook for the future I.
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects; D002170:Canada; D055598:Chemical Phenomena; D002621:Chemistry; D003276:Contraceptives, Oral / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D004338:Drug Combinations; D004967:Estrogens; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism; D008598:Menstruation / Q000187:drug effects; D011372:Progestins; D013256:Steroids; D013923:Thromboembolism / Q000139:chemically induced / Q000453:epidemiology / Q000401:mortality; D013924:Thrombophlebitis / Q000139:chemically induced; D006113:United Kingdom; D014481:United States
D003276:Contraceptives, Oral; D004338:Drug Combinations; D004967:Estrogens; D011372:Progestins; D013256:Steroids; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone